M & A

Morphosys: more antibodies

TecDax-listed biotech concern Morphosys AG is looking to purchase lantipeptide technology from Lanthio Pharma. Its purpose is the pursuit of research into active ingredients and the completion of its development portfolio on therapeutic antibodies. No details have been released on the financial aspects of the transaction that began with a 2012 cooperation agreement and purchase option between the two companies. By exercising its option rights Mophosys obtains all the patents pertaining to the lantipeptide technology. Lantipeptides comprise a new class of therapeutic products with improved active ingredients that have a very high specialisation potential and will probably be used in the treatment of diseases that do not normally respond to antibodies

Nemetschek: Shopping in the US

Nemetschek AG, producer of software for architects has bought up its US competitor Blubeam for 100 million dollars. The takeover is expected to be funded by shareholders’ equity and loans. The purchase price also comprises earn-out components pegged to turnover growth and profitability until 2016.

Blubeam offers pdf workflow solutions for computerised work processes and input from the building trade with over 650,000 users worldwide. TecDax listed Nemetschek is poised not only to increase its portfolio but also broaden its presence in the United States market. Nemetschek sees Blubeam as a growing company whose 2013 turnover rose by 48% to 22 million dollars and who has already posted a 2014 first semester turnover of 16 million dollars. Bluebeam will also benefit from Nemetschek’s consolidated presence in Europe and Asia, and will retain its autonomy.